Recombinant collagen for cosmetics

01Overview and value chain

Markers: [EC: EU Cosmetics Regulation (EC 1223/2009) & animal-testing ban | OECD: Bio-based skincare & beauty ingredients | Regulator: FDA (US), EMA (EU), NMPA (China)]

Recombinant collagen for cosmetics is engineered specifically for topical skincare and injectable aesthetic medicine, produced via precision fermentation in Pichia pastoris yeast or E. coli engineered to co-express human prolyl-4-hydroxylase (P4H) alongside collagen genes, yielding a protein with full human sequence identity, no prion or viral contamination risk, and — critically for cosmetic penetration — controllable low molecular weight (5-10 kDa mini-collagen fragments) able to cross the epidermal barrier that intact 300+ kDa animal collagen cannot. Giant Biogene, based in Xi’an and founded in 2000 by chief scientist Prof. Fan Daidi (who began collagen biomaterials research in 1994), is the world’s largest recombinant collagen producer; its Collgene and Comfy (可复美) skincare brands built on “Human-like Collagen” generate hundreds of millions of dollars in annual revenue. Jinbo Bio-pharmaceutical (listed on the Beijing Stock Exchange, ticker 832982.BJ), the leader in injectable recombinant collagen through its Weiyimei (薇旖美) brand of recombinant Type III humanized collagen, reported H1 2025 revenue of RMB 859 million (+42.43% year-on-year) and net profit of RMB 392 million (+26.65%), with over 2.7 million units of its collagen medical device used clinically — though growth decelerated sharply from the 90-180% rates seen in 2023-2024, a signal the sector’s earlier hypergrowth phase is maturing. In the US, Geltor introduced HumaColl21 Select in March 2026, a Type XXI collagen-based “matrikine” complex using precision proteolysis to concentrate biomimetic signaling peptides for topical skin health, building on its earlier HumaColl21 and Collume cosmetic ingredients. Germany’s Evonik launched VECOLLAN, a fermentation-based recombinant collagen mimicking the natural triple-helix structure, first as a vegan cosmetic ingredient in February 2024 and then in a clinical-grade version for clinical trials and medical device development in September 2025. BASF, partnering with Bota Biosciences, launched SkinNexus Collag3n in June 2026 — a 100% human-identical recombinant Collagen III fragment for the personal care market, alongside its NeoHelix Regenerate adaptive collagen rejuvenation ingredient, both debuted at in-cosmetics Global in April 2026.

The key directions of recombinant collagen for cosmetics are:

1. Topical skincare collagen: low-molecular-weight recombinant collagen fragments engineered to penetrate the epidermal barrier and stimulate fibroblast activity, unlike surface-sitting animal collagen.
2. Injectable aesthetic collagen: full triple-helix recombinant human collagen (typically Type III) manufactured to medical-device purity for dermal fillers and wrinkle-correction injections.
3. Matrikine and signaling-peptide technology: precision proteolysis of collagen fragments to concentrate specific biomimetic peptides that signal skin cells to synthesize their own neocollagen.
4. Vegan and cruelty-free certification: full elimination of animal-derived material, meeting Millennial and Gen Z consumer demand for cruelty-free, vegan-certified beauty ingredients.

Sectoral value chain

[Genetic design of collagen genes] ──> [Precision fermentation (yeast/E. coli)] ──> [Chromatographic protein purification]
                                                                                                        │
                                                                                           (Conditioning & stabilization)
                                                                                                        │
               [Premium cosmetic cream/filler] <─── [Formulation into emulsion recipes] <─── [LIMS purity & structure control]

Value chain levels

Cross-cutting technologies of the sector:

• P4H co-expression for triple-helix stability: integrating human P4H genes into the host alongside collagen genes drives intracellular prolyl-hydroxylation, letting synthesized peptide chains spontaneously fold into a thermostable triple helix resistant to enzymatic breakdown at skin temperature (37°C).
• Ion-exchange and hydrophobic chromatography: a cascade of cation-exchange resin (binding collagen at low pH, eluting with a salt gradient) followed by hydrophobic-interaction chromatography removes bacterial pyrogens and impurity proteins, achieving over 98.5% purity with endotoxin levels below 0.1 EU/mg.
• Matrikine signaling-peptide concentration: precision proteolysis breaks collagen into specific biomimetic fragments recognized by integrin receptors (alpha2beta1) on fibroblasts, triggering an intracellular signaling cascade that drives the skin’s own neocollagen synthesis.

02US

The United States hosts pioneering biodesign companies that hold foundational patents in recombinant cosmetic collagen and continue introducing new signaling-peptide technology.

Geltor’s HumaColl21 Select matrikine launch, foundational cosmetic-collagen patents, INCI registration via PCPC

• Geltor: introduced HumaColl21 Select in March 2026, a Type XXI collagen-based matrikine complex using precision proteolysis to concentrate biomimetic signaling peptides for topical skin health, building on its earlier HumaColl21 (the first 100% human Type XXI collagen for cosmetics) and Collume vegan collagen.
• INCI registration: the US Personal Care Products Council (PCPC) coordinates assignment of unique INCI codes for new recombinant collagen types (such as sh-Polypeptide-121), a mandatory step before commercial cosmetic launch.
• Patent leadership: Geltor holds foundational US patents in biodesigned cosmetic protein technology, positioning it as the reference point other recombinant-collagen cosmetic developers build against.

03CN

China is the undisputed global leader in recombinant collagen manufacturing scale, clinical adoption and commercialization, anchored in Xi’an’s “collagen valley” cluster, though 2025-2026 data shows the sector’s hypergrowth phase decelerating.

Giant Biogene’s global production leadership, Jinbo Bio-pharmaceutical’s injectable dominance and growth deceleration, Shaanxi’s national collagen hub

• Giant Biogene: based in Xi’an and founded in 2000 by chief scientist Prof. Fan Daidi, is the world’s largest recombinant collagen producer using high-yield E. coli expression; its Collgene and Comfy skincare brands built on “Human-like Collagen” generate hundreds of millions of dollars in annual revenue.
• Jinbo Bio-pharmaceutical: the leader in injectable recombinant collagen through its Weiyimei brand of recombinant Type III humanized collagen, reported H1 2025 revenue of RMB 859 million (+42.43% year-on-year) with over 2.7 million units used clinically, though growth decelerated sharply from the 90-180% rates seen in 2023-2024, signaling the sector’s earlier hypergrowth is maturing into a more normalized expansion phase.
• National hub status: recombinant collagen synthesis is listed among China’s national development priorities, with Shaanxi province established as a global hub (“collagen valley”) for recombinant protein manufacturing.

04EU

The European Union’s strict animal-testing ban drives demand for recombinant collagen validated through in silico and 3D-epidermis testing rather than live-animal trials, with major chemical groups now launching flagship products.

Evonik’s VECOLLAN clinical-grade launch, BASF-Bota Biosciences’ SkinNexus Collag3n, EU animal-testing ban as market driver

• Evonik: launched VECOLLAN, a fermentation-based recombinant collagen mimicking the natural triple-helix structure, first as a vegan cosmetic ingredient in February 2024 and then in a clinical-grade version for clinical trials and medical device development in September 2025.
• BASF and Bota Biosciences: launched SkinNexus Collag3n in June 2026, a 100% human-identical recombinant Collagen III fragment for personal care, alongside the NeoHelix Regenerate adaptive collagen rejuvenation ingredient, both debuted at in-cosmetics Global in April 2026.
• Animal-testing ban as driver: EU Cosmetics Regulation (EC 1223/2009) fully bans animal-tested cosmetics sale, making recombinant proteins validated via in silico modeling and 3D-epidermis testing the natural choice for European brands seeking cruelty-free, scientifically substantiated anti-aging actives.

05Leading companies and research institutes

06Tech stack and innovations

The recombinant cosmetic collagen stack pairs precise genetic engineering with pharmaceutical-grade purification and signaling-peptide science:

1. Genetic engineering and P4H co-expression for triple-helix assembly:
   • Natural collagen’s triple-helix stability comes from prolyl-4-hydroxylase (P4H)-mediated hydroxylation of proline residues in Gly-Pro-Hyp peptide repeats; since E. coli and yeast lack this enzyme in the needed configuration, human P4H subunit genes are co-transfected alongside collagen genes, letting synthesized chains spontaneously fold into a thermostable triple helix resistant to enzymatic breakdown at 37°C skin temperature.
2. Downstream purification and pyrogen removal:
   • Culture medium (especially from E. coli) contains dangerous bacterial pyrogens (lipopolysaccharides) that trigger inflammatory skin reactions; a chromatography cascade — ion-exchange resin, hydrophobic-interaction chromatography, then 30 kDa-cutoff ultrafiltration — achieves protein purity above 98.5% with endotoxin content below 0.1 EU/mg.
3. In silico efficacy verification:
   • Molecular-dynamics computational modeling calculates how well recombinant collagen fragments bind integrin receptors (alpha2beta1) on human fibroblasts, predicting the intracellular signaling cascade that drives the skin’s own neocollagen synthesis before physical testing begins.

07Value chains and production pipelines

Industrial pipeline for continuous production of purified recombinant human Type III collagen via Pichia pastoris fermentation at a CDMO facility (cGMP/ISO 9001/ISO 22716)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. P. pastoris strain      │ ───> │ 2. High-density fed-batch  │
│    inoculation (with P4H gene) │      │    fermentation (100 m³)       │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Multi-stage IEX/HIC     │ <─── │ 3. Centrifugation & TFF    │
│    chromatography purification │      │    ultrafiltration              │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Freeze-drying            │ ───> │ 6. Circular dichroism,     │
│                                │      │    LIMS quality certification  │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: P. pastoris strain inoculation with P4H gene

A 1 m³ seed bioreactor is loaded with sterile YPD growth medium and inoculated with a recombinant Pichia pastoris strain carrying synthetic genes for the human Type III collagen alpha-1 chain and co-expressed P4H, cultivated for 24 hours to reach stationary-phase biomass.

Stage 2: High-density industrial fermentation with methanol induction

Seed material is transferred to a 100 m³ industrial fermenter; the initial phase runs on glucose for rapid cell-density buildup, then automatic methanol feed (activating the AOX1 promoter) begins once glucose depletes, with fermentation continuing for 96 hours at 28±0.2°C under 0.2 MPa pressure with pure oxygen supply, as the yeast secretes the synthesized triple-helical collagen directly into the culture medium.

Stage 3: Centrifugation and TFF ultrafiltration

The culture broth passes through a high-speed tangential decanter centrifuge to remove yeast cells as sludge, with the clarified centrate containing the target protein directed to a tangential-flow-filtration (TFF) system with a 50 kDa membrane cutoff for 20x concentration and simultaneous diafiltration against sodium phosphate buffer (pH 6.5).

Stage 4: Multi-stage IEX/HIC chromatography purification

The concentrated protein solution passes through a cation-exchange resin column (SP Sepharose Fast Flow) at low pH, binding collagen while yeast impurity proteins wash out, then elutes via salt gradient onto a second hydrophobic-interaction column (Phenyl Sepharose) for final purification and deep pyrogen removal, yielding protein purity above 99%.

Stage 5: Freeze-drying

The purified collagen solution is sterile-filtered through a 0.22 μm membrane, frozen in trays at -45°C, then freeze-dried over 36 hours under deep vacuum with gradually rising temperature to +25°C, yielding a light, white, sponge-like powder of recombinant Type III collagen.

Stage 6: Circular dichroism and LIMS quality certification

A 5 g sample is taken from each 50 kg batch for quality control; circular dichroism spectroscopy across 190-260 nm confirms proper triple-helix folding (a characteristic positive peak at 220 nm and negative peak at 197 nm), SDS-PAGE electrophoresis confirms molecular weight (120 kDa) and purity, and results are logged into the LIMS system, which generates an electronic quality certificate under ISO 22716 (cosmetic GMP) standards before shipment to premium cosmetic brand manufacturers.